What is Strados Labs?
Headquartered in Philadelphia, Strados Labs specializes in the development of smart sensor technology designed to detect and predict compounding conditions associated with serious, chronic respiratory diseases. The company's flagship platform, RESP, has achieved significant regulatory milestones, including CE Mark certification and FDA Class II 510(k) clearance. By integrating proprietary algorithms with wearable hardware, Strados Labs provides clinicians and patients with actionable data, effectively bridging the gap between episodic care and continuous health monitoring. The firm is currently expanding its technological footprint to address a broader spectrum of chronic illnesses, including asthma, COPD, and infectious respiratory diseases, with strategic plans to incorporate heart failure monitoring into its diagnostic suite.
How much funding has Strados Labs raised?
Strados Labs has raised a total of $6.4M across 3 funding rounds:
Unspecified
$1.8M
Debt
$117K
Other Financing Round
$4.5M
Unspecified (2019): $1.8M with participation from Ben Franklin Technology Partners Companies, Cathexis Ventures, and SOSV
Debt (2021): $117K led by PPP
Other Financing Round (2022): $4.5M supported by SOSV, Blu Venture Investors, Wavemaker Three-Sixty Health, cultivate, and Broad Street Angels
Key Investors in Strados Labs
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
Blu Venture Investors
Blu Ventures is an early-stage venture capital fund specializing in cybersecurity and technology investments, providing strategic guidance to help companies scale from inception to exit.
Wavemaker Three-Sixty Health
Wavemaker Three-Sixty Health is a leading U.S. venture capital fund that focuses exclusively on early-stage healthcare startups, aiming to improve patient experiences and lower costs through disruptive innovation.
What's next for Strados Labs?
With the recent influx of capital, Strados Labs is poised to accelerate its commercialization strategy and expand its pipeline of smart sensor platforms. The company's roadmap for the coming fiscal periods focuses on scaling its respiratory health solutions while diversifying into new therapeutic areas. By capitalizing on its regulatory successes and robust data-driven insights, Strados Labs aims to solidify its role as a critical infrastructure provider in the evolving landscape of chronic disease management. The strategic deployment of these funds will likely prioritize market penetration, clinical validation for new indications, and the enhancement of its machine learning capabilities to improve patient outcomes and reduce healthcare costs.
See full Strados Labs company page
